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Executive summary
Although many studies document the pervasiveness and perniciousness of HIV stigma and 
discrimination, no research to date has attempted to quantify how stigma might undermine 
HIV programmes or explored the potential bene ts of stigma reduction programmes. These are 
important evidence gaps. Decisions about the scale, intensity and investment of HIV programme 
e orts require better information about the in uences of stigma. Without this knowledge, we 
cannot adequately address stigma and discrimination experienced by people living with HIV and 
cannot achieve optimal e ectiveness of HIV programmes in prevention, care and treatment.
This analysis estimates the potential impact of stigma on mother-to-child transmission outcomes. 
It represents an initial step toward addressing these evidence gaps. Although prevention 
programmes have the potential to minimize transmission of HIV from mothers to infants, 
substantial levels of dropout and lack of adherence to prescribed drug and feeding protocols 
compromise results. This is due to many factors, including problems related to the accessibility 
of services, the continuity of tests and drug supplies, the costs of accessing care, and whether 
women traditionally deliver in health facilities. A review of current evidence highlights that HIV 
stigma and women’s fear of violence if their status becomes known is an important barrier. This 
analysis employs a mathematical model to project the impacts of stigma on service use and infant 
infections under di erent scenarios, including varying levels of stigma, HIV prevalence among 
women accessing antenatal care services, and health system capacity.
The  ndings suggest that stigma might have a large impact on mother-to-child transmission, 
and programmes that can e ectively reduce stigma would be bene cial to women and children. 
Findings suggest that stigma might be responsible for more than half of mother-to-child infections 
in some settings. A highly e ective stigma reduction programme could reduce infant infections by 
as much as 33 percent. Based on these  ndings, investments of between $1 and $10 per woman 
attending antenatal care services could be cost-e ective, with higher levels of investment merited 
in settings with higher levels of HIV prevalence.
Since this work is exploratory, the estimates provided are best viewed as an initial step in providing 
concrete information for decision making and a practical framework for further research. The 
impact projections depend on assumptions about the extent to which stigma in uences the 
uptake of and adherence to prevention of mother-to-child transmission programmes, and 
assumptions about potential improvements resulting from stigma reduction programmes. The 
model inputs are based upon a limited body of available data and, in a number of cases, re ect 
best-guess estimates. The model also considers general scenarios rather than modelling speci c 
health systems and settings.
Although exploratory, the  ndings nonetheless illustrate that investment in stigma reduction 
could be an important and cost-e ective addition to current prevention of mother-to-child 
transmission programming. The model indicates how the loss of individuals at each service point 
in mother-to-child prevention programming has substantial and cumulative e ects, increasing the 
likelihood of transmission and morbidity. To date, a large focus of prevention of mother-to-child 
transmission programming has been on strengthening the delivery of the medical components of 
programming. This modelling exercise highlights the importance of investment in addressing the 
social barriers to service use as well, particularly stigma, as part of mother-to-child HIV prevention 
programmes.
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Introduction
Researchers have widely documented the pervasiveness of HIV stigma and discrimination, and 
the damage these in ict on people living with HIV and their families. Yet, to date, no research 
has attempted to quantify how stigma, in its various forms, might undermine HIV prevention, 
treatment and care programmes. This is a critical evidence gap. Decisions on the intensity and 
scale of programme e orts are increasingly based on cost and cost-e ectiveness data. Without 
these data, it might be di  cult to secure funding for an expanded response to stigma and 
discrimination, resulting in inadequate programming in these areas.
This analysis, which quanti es the potential e ects of stigma on mother-to-child transmission, 
or vertical transmission, is a preliminary step toward addressing this evidence gap. Although 
programmes to prevent mother-to-child transmission have the potential to minimize infant 
HIV infections, programme dropout and inadequate adherence to prescribed drug and feeding 
regimens compromise results. HIV stigma and discrimination are important factors, along 
with other gender factors like inequality and violence against women, in deterring service use 
and adherence, which contributes to transmission and morbidity. This working paper uses a 
mathematical model to project the potential magnitude of the e ects of stigma on programme 
outcomes and mother-to-child transmission of HIV. The  ndings below describe the model’s 
approach, structure and results.
Methods: modelling stigma and prevention of 
mother-to-child transmission
Development of the modelling approach involved multiple stages. We  rst reviewed current 
evidence on the impact of stigma on di erent forms of HIV programming. Based on this review, 
the authors developed draft model structures for programming and analysis. The authors agreed 
to focus on stigma and HIV programming for prevention of mother-to-child transmission (PMTCT) 
because of the growing recognition of the e ect of stigma on PMTCT programs, the serious 
implications for the health of mother and infants, and the clear pathways through which stigma 
a ects each step in the PMTCT service delivery process.
How does stigma infl uence PMTCT: model structure
PMTCT is a comprehensive, multistep prevention programme that follows women from antenatal 
care (ANC) through postdelivery services. Figure 1 describes, in a simpli ed, linear fashion, 
the optimal steps of PMTCT that HIV-positive pregnant women follow. The process begins 
with attending ANC, being o ered and accepting an HIV test. Next, women and infants take 
antiretroviral medications (ARVs) and then follow feeding guidelines to reduce transmission 
during infant feeding.1 This process is often described as the “PMTCT cascade,” because women 
are frequently lost to follow-up at di erent stages of the process or are not able to adhere to some 
components of the recommended guidelines (such as following feeding guidelines).
Figure 1. Typical PMTCT process
Attend ANC 
and o ered 
HIV test
Accept HIV 
testing
Receive HIV 
test results
ARV 
prophylaxis 
for mother
Deliver with 
health care 
attendance
ARV 
prophylaxis 
for infant
Follow 
feeding 
guidelines
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Over the past decade, as new evidence has become available, the speci c guidelines and service 
delivery practices at each point in the PMTCT process have evolved. The World Health Organization 
(WHO) issued new PMTCT guidelines in November 2009.*2;3 However, for the purpose of this 
modelling exercise, we have followed what has been, until recently, the commonly recommended 
practice in many parts of sub-Saharan Africa around drug prophylaxis (single-dose nevirapine for 
mother at onset of labour and for infant within 72 hours of birth) and infant feeding (exclusive 
breastfeeding for the  rst six months).
In addition, to facilitate the modelling exercise, we combined several of the steps (see Figure 2). 
Speci cally, being o ered, accepting and receiving an HIV test result were combined into one 
step. After testing, the next step is the mother’s receiving and taking single-dose nevirapine (with 
the assumption that the dose is taken at the prescribed time). Whether or not delivery occurs in 
a health facility, which has been shown to increase adherence,4 is factored into two steps in our 
model—whether the mother takes single-dose nevirapine, and whether the infant receives dosing 
within 72 hours. Next, the model looks at a mother’s ability to exclusively breastfeed for six months. 
Finally, the model considers the e ect of stigma on these four points in the PMTCT service delivery 
process, as illustrated by the two shaded areas in Figure 2.
Figure 2. Specifi c PMTCT process considered in the model
In the absence of stigma
In the presence of stigma
Exclusively 
breastfeed 
for 6 
months
Infant 
receives 
single-dose 
nevirapine 
within 72 
hours of 
birth
HIV-
infected 
mothers 
receive 
and ingest 
single-dose 
nevirapine
O ered, 
accept and 
receive HIV 
testing and 
results
Starting
point:
100,000
women
attending
ANC
Throughout this linear course, attrition occurs at each stage of PMTCT. At each step of the cascade, 
women face barriers to following the recommended actions and may not complete the process, 
thereby increasing morbidity and the potential for infant infection.
Figure 3 illustrates the pathways of women who are and are not HIV infected when in the PMTCT 
process, as de ned for this modelling exercise. It shows how these pathways  lter into the model’s 
two main outcomes of interest: vertical infections and knowledge of HIV status. For women 
entering ANC, the  rst branch in the pathway is refusing or accepting (and receiving) an HIV test. 
Women who accept the test follow the top trajectory initially, while those who do not, whether HIV 
positive or negative, follow the bottom one. Women who accept a test and are HIV negative then 
fall out of the top pathway and are included in the model calculations only to explore the impacts 
of stigma on the numbers of women who know their HIV status.
The top pathway then follows pregnant women who know they are HIV positive. Women may or 
may not take up single-dose or short-course nevirapine, and their infant may or may not be given 
* WHO issued new PMTCT guidelines in November 2009 related to ARV treatment and infant feeding. The guidelines suggest 
pregnant women with severe or advanced clinical HIV infection, or a CD4 cell count below 350 cells/mm3 regardless of symptoms, 
initiate lifelong antiretroviral therapy. In addition, WHO recommends all HIV-positive mothers begin a daily zidovudine or a three-
drug regimen at 14 weeks and continue through the end of the breastfeeding period. In addition, ARV prophylaxis, speci cally, 
daily single-dose nevirapine, is recommended for the infant during breastfeeding. As for feeding practices, WHO is developing 
guidance for national authorities to promote either exclusive breastfeeding with ARV prophylaxis or exclusive replacement feeding, 
depending on the quality of water available and the accessibility of formula. In conditions where breastfeeding is the better option, 
WHO strongly recommends exclusive breastfeeding for the  rst six months of life and continued breastfeeding through 12 months.
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single-dose nevirapine within 72 hours after birth. Finally, women may or may not adhere to six 
months of exclusive breastfeeding. The uppermost stream (upper solid-line boxes) of the top 
pathway shows the ideal intervention pathway for women who are HIV positive, in which women 
and infants are provided with and adhere to medication, as well as to feeding guidelines. For these 
women, the resulting risk of mother-to-child HIV infection is substantially reduced in contrast to 
HIV-positive women in any of the lower pathways.
Women in the lower pathway of the top stream (middle dashed-line boxes) represent women who 
adhere to one or more initial steps in the PTMCT process but are not able to participate fully in all 
the steps. The lowest pathway for HIV-positive women (lower dashed-line boxes) indicates women 
who did not test for HIV, and hence do not know whether they are HIV positive.
When using the model, pregnant women will diverge across di erent pathways during PMTCT 
depending on the underlying prevalence of HIV in the population of women accessing ANC and 
the degree to which they are a ected by HIV stigma and other factors, including the strength of 
the local health care system.
All HIV-positive women, no matter which pathway they take, are factored into the calculations for 
the model outcome on number of vertical transmissions. HIV-negative women are not factored 
into this outcome. For the model outcome—number of women who know their HIV status—all 
women are included.
Figure 3. Pathways of pregnant women through PMTCT model
Best-case scenario
Numbers 
(#s) 
accessing 
services
#s don’t 
accept 
HIV test
#s accept 
HIV test & 
receive result
#s HIV+ 
know status 
& mother 
takes 
nevirapine
#s child 
takes 
nevirapine
#s mother 
adheres to 
6 mos. exclusive 
breastfeeding
#s HIV+ 
don’t know 
HIV status & 
don’t receive 
PMTCT
#s HIV+ 
know status 
& mother 
doesn’t take 
nevirapine
#s child 
does 
not take 
nevirapine
#s mother 
does not 
adhere to 
6 mos. exclusive 
breastfeeding
Number of 
vertical HIV 
infections 
with and 
without 
stigma
⎫ 
⎪ 
⎪ 
⎪ 
⎪ 
⎬ 
⎪ 
⎪ 
⎪ 
⎪ 
⎭
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Model parameterisation
The modelling process considered both epidemiological inputs and inputs describing the 
estimated e ects of di erent levels of stigma (stigma inputs) for each step in the PMTCT cascade. 
These inputs were used to project the number of mother-to-child (vertical) HIV infections. Figure 4 
shows how these epidemiological and stigma inputs are utilised in the model.
Figure 4. Model inputs
Epidemiological 
inputs
Stigma 
inputs
Proportion 
of women 
o ered 
HIV test
E ect of 
stigma on 
uptake of 
VCT
HIV prevalence 
of women 
accessing 
ANC in setting 
modelled
E ect of 
stigma on 
mother taking 
nevirapine
Impact of 
ARVS on 
probability of 
MTCT
E ect of 
stigma on 
child taking 
nevirapine
Impact of 
recommended 
feeding on 
probability of 
MTCT
E ect of 
stigma on 
adherence 
to feeding 
guidelines Number of 
vertical HIV 
infections 
with and 
without 
stigma
⎫ 
⎪ 
⎬ 
⎪ 
⎭
Notes: VCT, voluntary counselling and testing; MTCT, mother-to-child transmission.
General inputs for size and levels of HIV infection among the population of 
women accessing antenatal care
The model requires general inputs about the particular ANC population that is being considered. 
These inputs are the number of women attending antenatal services, the levels of HIV infection 
in the ANC population, and the percentage of women who either die or lose their child during 
pregnancy or in  rst year of life. For this modelling exercise, the authors assume an initial cohort 
of 100,000 women entering ANC, a range of potential levels of HIV infection among women 
attending antenatal services (15%, 10%, 5%), and a 5% mortality rate.
Epidemiological inputs on the probability of mother-to-child transmission
The model incorporates  ve epidemiological inputs that describe the probability of vertical 
transmission in di erent levels of adherence to the PMTCT cascade (Table 1). The probabilities 
are based on a review of current evidence of transmission probabilities in various prevention 
scenarios. The highest transmission probability is in the absence of PMTCT and when the mother 
is not able to undertake six months of exclusive breastfeeding. The lowest transmission probability 
is when both the mother and child receive nevirapine and the mother is able to adhere to six 
months of exclusive breastfeeding. It is worth noting that lower transmission probabilities for 
best-case scenarios are achievable if the mother receives antenatal ART and post-natal ART during 
breastfeeding.
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Table 1. Probability of transmission from HIV-infected mother to child in fi rst year of life
Probability description % References
Probability of vertical transmission in absence of PMTCT 32% 5–7
Probability of vertical transmission when mother receives nevirapine, 
child does not, and mother is not able to adhere to feeding guidelines
20% 8;9
Probability of vertical transmission when mother receives nevirapine, 
child does not, and mother is able to adhere to feeding guidelines
13% 9;10
Probability of vertical transmission when mother and child receive 
nevirapine and mother is not able to adhere to feeding guidelines
8% 11–14
Probability of vertical transmission when mother and child receive 
nevirapine and mother is able to adhere to feeding guidelines
5% 12;14–16
Stigma inputs
A key element of the model is the incorporation of numerical inputs describing how stigma may 
reduce women’s ability to adhere to di erent components of the PMTCT programme, such as 
receiving her HIV test result, receiving the necessary medication, or being able to consistently 
follow the feeding guidelines.
Based upon our review of existing evidence, the model assumes that the greater the level of 
stigma in a setting, the greater the challenges for PMTCT programming. However, this is di  cult 
to quantify accurately; and following initial feedback from experts, we decided to have the model 
compare the potential impact of four di erent levels of stigma (none, low, medium and high).
This approach makes it possible to estimate the proportion of vertical infections due to stigma and 
to explore how reductions in stigma could in uence transmission levels. For example, the model 
can indicate how many infections might be averted by reducing stigma from high to medium or 
from medium to low. The stigma model inputs re ect the in uence of di erent levels of stigma* 
on mother-to-child HIV transmission through the proportions of HIV-positive and HIV-negative 
women who follow di erent pathways. In addition, the inputs take into account the range of 
health system, economic and cultural in uences. These include the accessibility of services, the 
continuity of tests and drug supplies, the costs of accessing care, and whether women traditionally 
deliver in health facilities. Each will also impact uptake of and adherence to PMTCT.
The e ect of other non-stigma-related factors, such as service accessibility, that might impact 
uptake and adherence are represented in the parameter values used for the no stigma scenario 
under each step in the process. The values used for the low, medium and high stigma scenarios 
represent the combined e ect of these other factors and the impact of stigma. In addition, two 
service delivery contexts (higher and lower functioning—see Table 2) are modelled to re ect the 
di erent impact stigma will have on vertical transmission, depending on how well the service 
delivery system functions.
* In this model we are considering stigma that occurs in the family, in the community and at the health care setting, as well as 
internalized, or self-, stigma.
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Table 2. Description of higher- and lower-functioning health care system settings
Higher-functioning health system setting Lower-functioning health system setting
ANC services routinely o er PMTCT services• 
opt-out HIV testing protocol—HIV testing is routinely • 
provided to all patients unless the client chooses not to 
be tested
pre- and posttest counselling• 
rapid testing (women receive test results before leaving • 
the clinic same day)
su  cient number of test kits and medication• 
nevirapine to women when they receive a positive test • 
result
good access to PMTCT services• 
higher proportions of women delivering at the health • 
care facility
testing is not always o ered by the health care provider• 
rapid testing may or may not be available• 
stock-outs of test kits and ARV medications occur• 
women must return to the facility for nevirapine • 
dispensing
limited access to facilities that o er PMTCT• 
less likelihood of delivery in the health facility• 
To estimate the speci c stigma inputs (see Table 3) for each of the four PMTCT steps in the model, 
the authors conducted an extensive literature review examining published and grey literature* 
on women’s participation along the PMTCT service delivery cascade10–13;17–30 and women’s reasons 
(stigma- and non-stigma-related) for nonparticipation in services.4;31–51
It should be noted that the literature describing women’s perspectives on PMTCT programmes 
and factors a ecting their ability to initiate and adhere to the full PMTCT protocol (from testing 
through infant feeding) is small and largely qualitative.4;31;33–35;44–46;48–50 Research into the relative 
roles of various factors in uencing adherence is even sparser.31;33–35;39;45;49 Quantitative data on 
the relative importance of factors in uencing uptake and adherence are unavailable. Because of 
this scarcity of quantitative data on stigma and other factors a ecting uptake, the authors made 
best-guess estimates of the stigma parameters, which were generally based on qualitative data. 
The literature reviewed and the process for arriving at the stigma parameter estimates for the four 
steps in the PMTCT process are described below.
Speci cally, the stigma estimates (Table 3) for each step were achieved via the following process. 
To begin, we considered the no stigma scenario, which is estimated to re ect all nonstigma factors 
a ecting uptake. To arrive at this estimate, we considered the available literature (qualitative and 
quantitative) documenting barriers to uptake (other than stigma), and participation rates across 
PMTCT programs in a range of contexts for each particular step (e.g., accepting an HIV test). Based 
on the in uence of non-stigma-related factors and participation rates, we selected a value on the 
high end of participation as our starting point for the no stigma estimate in the higher-capacity 
settings, and on the lower end for the no stigma estimate for low-capacity setting.
The next step was to consider how this participation rate might drop in the presence of high levels 
of stigma. Available literature suggests that stigma is a large barrier to uptake and adherence. 
Combining the qualitative evidence with the sparse quantitative data, the authors estimated the 
parameters conservatively with respect to the in uence of stigma on uptake, choosing parameter 
values in the middle to low end, rather than on the higher end. Next, as data available do not 
* A search was conducted on PubMed and Google Scholar using combined phrases of PMTCT or mother-to-child transmission with 
stigma, discrimination, retention, adherence, drop out and participation. A search for grey literature was conducted with similar 
terms on Web sites of multilateral organizations, such as UNAIDS and WHO; bilateral organizations, such as DFID and PEPFAR; and 
international nonpro t organizations, such as Family Health International and Elizabeth Glaser Pediatric AIDS Foundation. The 
references sections of all articles found were consulted for additional relevant literature. A total of 65 articles were reviewed.
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distinguish between levels of stigma, we estimated values for low stigma and medium stigma by 
evenly distributing the point di erence between high stigma and no stigma.*
Finally, we assume that the only di erence between the high- and low-functioning service delivery 
settings is in the starting point (the no stigma estimate), which re ects the di ering impact of health 
systems factors on uptake and adherence. The relative e ect of each level of stigma (low, medium, 
high) is assumed to remain the same across both high- and low-functioning service delivery settings.
Table 3. PMTCT stigma inputs
 Lower Functioning Health System Setting Higher Functioning Health System Setting
 No 
stigma
Low 
stigma
Medium 
stigma
High 
stigma
No 
stigma
Low 
stigma
Medium 
stigma
High 
stigma
1. Proportion of 
women attending ANC 
who are o ered and 
accept HIV test and 
receive results
83% 80% 77% 74% 98% 95% 92% 89%
2. Proportion of 
women who test HIV 
positive,  nd out status 
and take nevirapine 
75% 65% 55% 45% 95% 85% 75% 65%
3. Proportion of 
women who test HIV 
positive and receive 
nevirapine whose 
infant receives infant 
dose 
40% 33% 27% 20% 82% 75% 69% 62%
4. Proportion of 
women who test HIV 
positive, receive ART 
and are able to adhere 
to feeding guidelines
35% 25% 15% 5% 65% 55% 45% 35%
Note: ART, antiretroviral therapy.
1. Proportion of women attending ANC who are offered and accept an HIV test
To estimate the no stigma inputs for the proportion of women attending ANC and accepting an HIV 
test, the authors reviewed available monitoring data from several PMTCT service sites.† From this 
data, we ascertained the testing rates of pregnant women under di erent testing protocols. The 
authors also reviewed the available literature on reasons (other than stigma) that pregnant women 
might refuse an HIV test or be unwilling to accept a hypothetical test. Based on this review, factors 
that may hinder or facilitate testing among pregnant women include knowledge of mother-to-
child transmission, awareness of and access to available PMTCT services, educational level of the 
mother, and availability of test kits and medication at ANC facilities. In Tanzania, for example, only 
53% of women sampled knew about the availability of medications and other services that can 
prevent mother-to-child transmission.52 In Nigeria, only 27% of 804 women attending antenatal 
services knew about the possibility of mother-to-child transmission.31
* For example, if 75% of women are estimated to participate in the no stigma setting, and 45% are estimated to participate in the 
high stigma setting, the di erence between these two extremes would be divided evenly between the low and medium stigma 
parameters to arrive at 65% for the low stigma setting and 55% for the medium stigma setting. 
† We reviewed data for opt-out testing, in which an HIV test is routinely given unless the patient states otherwise; rapid testing, in 
which testing and diagnosis occur within 20–30 minutes; and voluntary counselling and testing (VCT), in which health providers 
may counsel the patient to receive an HIV test but the process is entirely voluntary.
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Because the lack of knowledge about mother-to-child HIV transmission and problems accessing 
HIV testing services appear to hinder pregnant women from HIV testing, experts believe that 
reducing these barriers will increase testing and participation in PMTCT services. It should be 
noted that the advent of rapid testing and opt-out testing in PMTCT settings is, in fact, improving 
testing rates, as a much higher proportion of women are testing and receiving their test result. As 
demonstrated by Botswana’s national “routine testing” campaign, with an opt-out rapid-testing 
initiative started in 2004, testing among the general population, particularly among women, 
has skyrocketed.53 Recent data from 2005 to 2007 show that more than 95% of pregnant women 
in Botswana accepted HIV testing at antenatal clinics.54 Monitoring data from PMTCT sites 
administered by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) also indicate increases 
in testing among pregnant women after instituting opt-out testing procedures. From 2000 to 
2007, before opt-out testing was implemented, 94% of pregnant women were counselled and 
78% accepted testing at EGPAF sites. From 2007 to 2008, after opt-out testing was made standard 
practice, 100% of women were counselled and 90% of pregnant women accepted testing.27
Based on this information, and the assumption that most PMTCT programs have or are shifting 
to rapid testing and opt-out protocols, the no stigma parameter for the high-functioning service 
delivery setting is estimated at 98%. The estimate is based on the assumption that, in the absence 
of stigma and in a high-functioning service delivery system, the majority of women (close to 100%) 
will be o ered and accept a test and receive their results.
In a low-capacity setting in which knowledge and awareness of PMTCT and access to PMTCT 
services are lower, and opt-out testing and rapid testing may not always be o ered, the parameter 
for no stigma is estimated at 83%. This estimate is based on monitoring data from EGPAF sites prior 
to 2007, in which 78% of pregnant women were tested and 72% of women retrieved their results.27 
The authors assume that a portion of test refusal and not receiving test results is due to stigma and 
therefore add to 78% an additional 5 percentage points, a portion of what we estimate for the high 
stigma setting (9%). Because the sites included in the study varied across settings and countries, 
the authors assume the degree of stigma present within the communities also varied between low 
and high prevalence.
To estimate how the proportion of women receiving testing and test results would change in the 
context of high stigma, the authors reviewed literature on women’s fears of involuntary disclosure 
and doubts about con dentiality of results, their anticipation of stigma and discrimination, 
and negative responses to a positive test result. Research demonstrates fear of stigma and 
discrimination impedes a woman’s decision to seek or accept an HIV test. Pregnant women are 
fearful of receiving a positive result and the negative reactions they may incur from health care 
workers, family, friends and/or the community.50 In Nigeria, 8% of women explained that their 
unwillingness to take an HIV test was due to feeling uncertain in their clinic’s ability to maintain 
con dentiality and privacy. The same study also showed that pregnant or postpartum women 
were signi cantly less willing to accept an HIV test if their perception of social support from family 
and community was low.31 In Uganda, 7% of women who were o ered an HIV test were fearful of 
a partner’s reaction and refused testing.35 Similarly, women who refused testing in Botswana were 
more likely to a  rm the statement “it is better to die without treatment than for other people to 
know you are HIV positive” than were those women who accepted an HIV test.34
Based on this literature and the monitoring data (discussed above) that shows 2% to 19% gaps 
between rates in testing acceptance and test result retrieval (the parameter for high stigma), it is 
conservatively estimated that 9% fewer women would be tested and receive their results in the high 
stigma setting compared with the no stigma setting. In a high-functioning service delivery setting, 
the testing rate among pregnant women attending ANC in the absence of stigma is estimated at 98%, 
while in a high stigma setting the estimate is 89%. Similarly, the estimates for the low-functioning 
service delivery setting are 83% in the absence of stigma, but in the presence of high stigma it is 74%.
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2. Proportion of women who take single-dose or short-course nevirapine
Researchers have proposed several non-stigma-related reasons for why women are unable 
to adhere to ARV prophylaxis. These include the severity of drug side e ects and the lack of 
con dence in the e  cacy of ARV prophylaxis.41 However, others found no evidence to support 
these two theories.39 It has also been proposed that the complex dosing schedule and/or the 
speci c time for ingestion may confuse women into missing their proper dosage.29 Data from 
Zambia indicate some women do not take their prescribed single-dose nevirapine because they 
“do not want to prevent their babies from getting HIV if there is no maternal treatment available.”55 
A study in Rwanda found a pregnant woman’s nonadherence is associated with an unmarried 
status, a lower educational level and less frequent ANC visits.37 In addition, women may have 
di  culty travelling to the closest facility that o ers PMTCT services, as demonstrated in a study of 
Malawi’s highly centralized PMTCT service delivery system.42 In Zambia, nonadherence of mothers 
was associated with home births (OR=3.15, 95% CI: 1.34 to 7.38).4 Similarly, in Rwanda, adherence 
was higher for health care facility delivery: 86% of adherent women delivered at the hospital, but 
only 28% of nonadherent women delivered at a health facility.37 Nonstigma- (e.g., distance, cost) 
and stigma- (fear of disclosure of status) related factors could in uence whether a delivery takes 
place in a health facility.
In addition to research examining potential reasons for nonadherence, the authors examined 
literature documenting rates of nevirapine uptake. From 2007 to 2008, EGPAF increased ARV 
uptake by expectant mothers at its PMTCT service delivery sites from 75% to 86% by dispensing 
nevirapine during posttest counselling.27 Research from South Africa indicates 95% of women 
attending health facilities received nevirapine, and in Rwanda, 94% of women who received single-
dose nevirapine understood health care providers’ ingestion instructions.29;37 Based on these data, 
and assuming that in the high-functioning health setting the vast majority of women will receive 
and take nevirapine (largely because they are delivering in the health facility where they received 
ANC testing and nevirapine), 95% of women in a high-functioning system who test positive are 
estimated to take nevirapine in the absence of stigma.
Data from the PEARL study, a multicountry study of PMTCT service delivery in Zambia, Cote 
d’Ivoire, Cameroon and South Africa, and from PMTCT service delivery sites administered by 
EGPAF prior to 2007, formed the basis for the no stigma estimate in the low-functioning setting. 
These data show that on average, across all 43 sites of the PEARL study, 71% of women received 
nevirapine, and across EGPAF sites prior to 2007, 75% received nevirapine.20;27 Although these 
numbers come from settings where stigma is probably high, they are used as the basis for the no 
stigma estimates because it is assumed that stigma is more likely to in uence whether women 
ingest the drug rather than whether they simply receive it. Based on this, 75% of women in low-
functioning settings who know their HIV status are estimated to adhere to nevirapine in the 
absence of stigma.
Both the qualitative and quantitative research highlights the association between HIV stigma and 
low drug adherence among pregnant women. Nondisclosure of status to partners, other family 
members and friends is considered a key factor related to both. Fearing negative reactions, women 
are selective regarding to whom they disclose. They choose most often to disclose to individuals 
who they feel have been supportive in the past.56 In a study from Zimbabwe, only 44% of pregnant 
women shared their positive status with siblings, and only 30% disclosed to their parents because 
they feared both involuntary disclosure and rejection if their status was disclosed. A total of 78% 
of participating women disclosed their positive status to their spouse. Of the 22% who did not 
disclose to their spouse, 35% feared the marriage would su er, 28% feared accusations of in delity 
and 14% feared domestic violence.57 In a study that analysed data from Rwanda’s national PMTCT 
programme, disclosure to family members or friends was signi cantly lower among nonadherent 
women than adherent women (62% vs. 82%, P < 0.001).37 Similarly, results from a study in Lusaka, 
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Zambia, show that women who deliver at home and have not disclosed their HIV status to their 
partner are signi cantly less likely to adhere to single-dose nevirapine than women who have 
disclosed to their partner (OR=5.33, 95% CI: 1.09 to 26.01).4
Based on the above literature, and drawing speci cally on  gures from the PEARL study and the 
evaluation of Rwanda’s national PMTCT initiative, the parameter for high stigma was set at 30% 
below the no stigma setting. The PEARL study, which collected cord blood samples to analyse 
single-dose nevirapine ingestion in participating women, demonstrated that of the women who 
received nevirapine and returned to deliver in a health facility (71%), only 57% had nevirapine in 
their cord blood. The range in this  gure across sites was large, from 5% to 87%, and this represents 
a best-case scenario in which women returned to the health facility to deliver.20 In Rwanda, of the 
women delivering at home, about 14% of women who been dispensed single-dose nevirapine but 
did not ingest it, expressed they were “afraid,” and another 10% explained that someone who did 
not know their status was present.37 Therefore, taking into account nonadherence due to stigma 
inside and outside the health facility, in a high-functioning setting, in the absence of stigma 95% of 
women who know their HIV status are estimated to take nevirapine, and in the presence of high 
stigma the estimate is 65%. In a low-functioning setting, in the absence of stigma 75% of women 
who know their status will take nevirapine, but in the presence of high stigma the estimate is 45%.
3. Proportion of infants who receive single-dose nevirapine within 72 hours after birth
To estimate the proportion of infants born to HIV-positive mothers who are administered single-
dose nevirapine within the recommended 72 hours after delivery in the no stigma scenario, the 
authors reviewed literature on infant dosing rates and reasons that some infants do not receive 
treatment. Explanations for low levels of adherence among newborn infants include poor neonatal 
health, perhaps associated with a mother’s low socioeconomic status or inadequate prenatal care4; 
delivery outside of a health care facility4;37; and a mother’s own nonadherence to nevirapine37;39; the 
latter two could also be due to stigma. In a study in Rwanda, 90% of infants born in a health facility 
received single-dose nevirapine, while 15% of infants delivered at home were brought to the clinic 
to receive nevirapine.37 Given the strong link between health facility delivery and adherence to 
infant dosing,4 rates of health care facility delivery among HIV-positive women are also taken into 
account. In studies from Zimbabwe and Zambia, 88% and 90% of HIV-positive women delivered at 
a health care facility, respectively.4;26
In a high-functioning setting, the assumption is that most women will deliver in a health facility 
and, in instances where women deliver at home, access to a nearby facility for infant dosing will be 
available. Based on this assumption and the above data, the parameter for no stigma in a high-
service-delivery setting was estimated as follows: 90% of women will deliver in a health facility, 
and of these women, 90% of their babies will receive infant dosing; or, 81% of infants born to HIV-
positive mothers will be delivered in a health facility and receive dosing within 72 hours of delivery. 
In addition, we estimate that of the 10% of women who deliver at home, 15% of their infants will 
be brought to a facility and receive single-dose nevirapine within 72 hours of delivery. Adding 
these two groups together, 82% of infants born to HIV-positive women in the high-functioning, no 
stigma setting are estimated to receive infant ARV prophylaxis.
For the low-functioning setting, where access to a health facility may be limited and travel may be 
di  cult to facilitate infant dosing, we estimate a signi cant decrease in the proportion of women 
delivering in a health care facility. Manzi et al. estimate 60% to 90% of all deliveries in rural sub-
Saharan Africa occur at home.42 Therefore, in the absence of stigma for a low-functioning setting 
and assuming 60% of women deliver in a health care facility, the parameter for no stigma and low 
functioning is estimated at 40%.
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To estimate the parameters for infant adherence in the presence of high levels of stigma, the 
authors considered research that demonstrates how the fear of disclosure impedes a mother’s 
choice to deliver in a health facility and share her HIV status with health care providers, a factor 
that is signi cantly associated with whether or not an infant is administered prophylaxis. Pregnant 
adolescent girls in South Africa voiced their fear of judgmental, unsympathetic health care workers 
who would gossip about their patients’ status, and as a result, hid their positive status from hospital 
sta  by not bringing their ANC card, which indicates their HIV status, to the health facility or by 
swapping their ANC card with a friend who was HIV negative.50 Additionally, qualitative data from 
Kenya suggests that women will avoid antenatal and delivery facilities in favour of traditional birth 
attendants at home because they fear disapproval and discrimination from health care providers.48 
Because an infant’s uptake of nevirapine is related to whether the mother delivers at home or in a 
health facility, we make the assumption that if 24% of women who delivered at home in Rwanda 
could not adhere to ARV prophylaxis due to fears of involuntary disclosure (as stated in the previous 
section), a similar proportion of women would not obtain infant prophylaxis for their newborn due 
to the same reason. In fact, in the same study, 18% of the women who delivered at home and did 
not receive nevirapine for their newborn explained that they did not have any assistance to bring 
the child into the health facility,37 a reason that might be due to nondisclosure to family and friends. 
Therefore, in both the low- and high-functioning settings, we have estimated a 20-point di erence 
between the proportion of infants who receive single-dose nevirapine in the absence of stigma 
and the proportion of infants who receive single-dose nevirapine in the presence of high stigma. 
Therefore, in a high-functioning setting, 82% of infants receive nevirapine in the absence of stigma, 
but the estimate is 62% in the presence of high stigma. In a low-functioning setting, 40% of infants 
receive nevirapine in the absence of stigma, but the estimate is 20% in the presence of high stigma.
4. Proportion of women who take nevirapine and adhere to feeding guidelines
To estimate the parameters for the no stigma scenarios, the authors reviewed literature 
documenting rates of exclusive breastfeeding among di erent populations and examining reasons 
that HIV-positive women are not able to follow exclusive breastfeeding guidelines. Because best 
practice feeding guidelines in the context of HIV transmission have varied greatly over the past 10 
years, mixed messaging and confusion are reasons some women do not adhere to the exclusive 
feeding guidelines. Researchers in South Africa and Malawi have documented the confusion 
women feel over which feeding practice—formula feeding or breastfeeding—is in the best interest 
of their newborn child.33;45;47 Low rates of exclusive breastfeeding among HIV-positive women 
are common in most African nations, with the exception of South Africa. In a survey of mothers 
attending antenatal services in Tanzania and Uganda, researchers found 19% and 48% of women, 
respectively, exclusively breastfeed their infant through age 4 months.28 In South Africa, within the 
 rst week of the infant’s life, the rate of exclusive breastfeeding is higher, reaching 56% among HIV-
positive women and 61% among HIV-negative women.58
Based on the proportions of women who exclusively breastfeed in di erent African countries 
and women’s additional HIV support and knowledge associated with a high-functioning health 
system setting, the parameter estimate for exclusive breastfeeding in the absence of stigma is set 
at 65%. This number is estimated to drop to 35% in a low-functioning setting, based on the ranges 
presented above and the assumption that counselling on feeding practices is more likely to be 
unclear or absent in a low-functioning setting.
Fear of involuntary disclosure and pressures from the family can in uence a woman’s ability to 
adhere to six months of exclusive breastfeeding; therefore, to estimate the parameters for high 
stigma, the authors examined available data on the e ects of women’s disclosure on their ability 
to exclusively breastfeed. In Malawi, Sibeko et al. found that mothers who had not disclosed 
their status were less able to adhere to exclusive breastfeeding or exclusive formula feeding and 
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were most likely to mixed feed,45 a practice that has been found to have the greatest risk of HIV 
transmission.15;59 Research from South Africa con rms the  ndings from Malawi. Of the women 
who intended to exclusively breastfeed, 80% introduced other liquids into their newborn’s 
diet because of pressure from family members. Sixty-four percent of women who intended to 
breastfeed exclusively did not adhere because they had not disclosed their status to their family.40 
If a woman does not disclose her HIV status and is fearful of involuntary disclosure, it may be more 
di  cult for her to adhere to one exclusive method of feeding practice. In general, community or 
family beliefs about early childhood nutrition dictate a new mother’s infant feeding behaviour.6;13;40 
Not following the cultural norms or her family’s recommendations on how best to support her 
child’s early nutrition could potentially signify she is HIV positive.
Because there is little data that quantify the association between disclosure and exclusive 
breastfeeding, the authors also looked at the proportion of HIV-positive women who intended 
to exclusively breastfeed in comparison with how many of those women successfully sustained 
the practice for six months. In Cote d’Ivoire, 32% of postpartum HIV-positive women who 
decided to breastfeed intended to breastfeed exclusively. After six months, the proportion of 
women exclusively breastfeeding fell to 3 percent.17 Similarly, in South Africa, 78% of HIV-positive 
women initially intended to exclusively breastfeed, and only 38% sustained this practice for six 
months.13 Based on this limited data and the authors’ best estimate, the parameter for the high 
stigma scenario is estimated at 30% lower than that of the no stigma scenario. Therefore, in high-
functioning health system settings, in the absence of stigma 65% of HIV-positive women will 
adhere to exclusive breastfeeding for six months, but in the presence of high stigma the estimate 
would be only 35%. In low-functioning health system settings, in the absence of stigma 35% of 
women will adhere to exclusive breastfeeding for six months, but in the presence of high stigma 
this number is estimated to fall to 5%.
Model impact projections
The model was then used to calculate how the di erent levels of stigma, with their associated 
impact, a ect rates of participation at the di erent steps of PMTCT, from HIV testing through to 
infant feeding.
Table 4 shows the model projections of the impact of stigma in the low- and high-functioning 
delivery systems for varying assumptions about HIV prevalence levels among women accessing 
antenatal care services (15%, 10%, 5%).
In the high-functioning setting, for example, it is projected that where ANC HIV prevalence is 15% 
and stigma is high, there would be 2,827 vertical HIV infections, but there would only be 1,342 
infections if there was no stigma. This suggests that more than half (53%) of vertical infections 
are attributable to stigma. The model projects proportionately smaller numbers of HIV infections 
averted in the 10% and 5% prevalence scenarios. In each case, the same percentage of HIV 
infections is due to stigma.
In the lower-functioning setting, with more challenges to the delivery of PMTCT services, the 
projected impact of stigma is still substantial. If the ANC HIV prevalence is 15% and stigma is high, 
the model projects that there would be 3,940 vertical HIV infections, while there would only be 
2,902 vertical transmission if there was no stigma—26% fewer infections. The model projects there 
would be 3,684 infections in the medium stigma scenario, and 3,303 infections in the low stigma 
scenario. Again, the proportion of HIV infections due to stigma does not vary by HIV prevalence.
Figure 5 and Figure 6 illustrate another way of viewing the potential impact of stigma in higher- 
and lower-functioning settings along the PMTCT cascade.
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Figure 5. Proportion of HIV positive women completing PMTCT cascade, 
high-functioning health system
Figure 6. Proportion of HIV positive women completing PMTCT cascade, 
low-functioning health system
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In the lower-functioning health service scenario, we project a larger number of potential HIV 
infections than in the higher health service setting, but a smaller percentage of infant infections 
attributable to stigma. This is because, in the lower-functioning setting, many other factors also 
contribute to transmission. This does not mean that stigma reduction programmes are less 
important in these settings but rather that a range of other important service improvements could 
also reduce transmission.
The model can also be used to explore how many HIV infections might be averted by reducing 
the levels of stigma in a community. This is done by comparing the number of HIV infections 
that would occur if levels of stigma were reduced from high to low, from high to medium or from 
medium to low.
For example, in a high-functioning setting with a 15% HIV prevalence, if a highly successful stigma 
reduction programme was able to reduce the level of stigma from high to low, the model suggests 
that 940 vertical infections might be averted (a reduction from 2,827 in high stigma to 1,887 in 
low stigma)—33% fewer HIV infections (also shown in the results in Table 4). Even a reduction in 
stigma from high to medium would reduce infections by 19%—translating to 445 fewer infections.
As would be expected, the projected number of HIV infections is in uenced by the underlying 
levels of HIV infection in the ANC population, with twice as many babies potentially becoming 
HIV infected, for example, in settings where twice as many pregnant women are HIV infected. 
However, the percentage projections of the contribution of stigma to vertical transmission, and 
the percentage reduction in vertical HIV transmission associated with reduction of stigma, do not 
depend upon HIV prevalence because these are relative measures of impact.
Projected thresholds for cost-effectiveness investment in stigma reduction
The question that will inevitably arise among donors and programme managers is whether 
addressing stigma is cost-e ective compared with other forms of investment. To explore this issue, 
drawing upon recent reviews of the cost-e ectiveness of HIV prevention and recommendations 
from the World Bank regarding appropriate cost-e ectiveness thresholds, we used a conservative 
cost-e ectiveness threshold of US$1,000 per HIV infection averted.60;61 Based on this threshold, it 
is then possible to use the impact  gures (shown in Table 4 ) to estimate what level of investment 
in stigma reduction would be cost-e ective, assuming that this investment would result in the 
speci ed improvements in service delivery (Table 5).
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The results suggest that stigma reduction investments of between $1 and $10 per woman 
attending ANC services would be cost-e ective, with higher levels of investment merited in higher-
HIV-prevalence settings or if stigma reduction programmes are able to achieve large reductions in 
stigma (say from high to low). In practice, it is likely that stigma reduction programmes will need 
both a health sector and a community focus to ensure that women feel able to be HIV tested, to 
access treatment and to follow recommended HIV treatment guidelines.
Although these cost projections are speculative, because they depend upon the assumption 
that the projected stigma reduction impacts can be achieved, they nonetheless illustrate that an 
investment in stigma reduction programming might be an important and cost-e ective addition 
to current PMTCT programming.
Limitations of the models
While the epidemiological modelling presented o ers important insights about potential 
interactions between stigma and HIV, modelling such as this has a number of important 
limitations.
The most fundamental limitation is the challenge of trying to realistically quantify the di erent 
dimensions of stigma for use in mathematical models. While some stigma-related behaviours 
(e.g., enacted stigma or discrimination) are overt, many are subtle (e.g., psychological reactions or 
interpersonal relations), making them complex to “measure.” The current absence of data on stigma 
makes it di  cult to determine the level of stigma, for example, no, low, medium or high. Similarly, 
it is di  cult to estimate how patterns of behaviour and/or service use could change if stigma 
was reduced or if there was no stigma. Although it is easy to hypothesise that the situation would 
improve in the absence of stigma, other constraints to service use might nevertheless remain, 
including other gender-related factors like male involvement. For this reason, the no stigma inputs 
should be used to re ect the e ects of other constraints on delivery of services.
For simplicity, this model also does not consider women who seroconvert while attending ANC 
services, that is, those who initially test as HIV negative but become HIV positive during pregnancy 
and therefore might transmit HIV to their infant. However, because these women would not be 
identi ed by an initial PMTCT intervention, the number of resulting vertical infections that occur 
due to this is unlikely to di er between the stigma and no stigma scenarios and therefore will not 
a ect the  nal model outcomes.
Our analysis was based upon common PMTCT practise in many developing country settings 
over the past years and does not re ect the new (2010) WHO guidance.2;3 However, since this 
guidance recommends moving away from single-dose nevirapine to a daily zidovudine or three-
drug regimen starting at 14 weeks of pregnancy and continuing through breastfeeding and daily 
nevirapine for the infant while breastfeeding, if anything, the current model underestimates the 
potential impact of stigma.
However, even using these “best guess” inputs and general scenarios, it is possible to gain 
important insights about the compounding impact of stigma. The structure of the models 
themselves demonstrates how the loss of individuals at each stage (e.g., those deterred by 
stigma) will have multiplying e ects, increasing the likelihood of transmission and morbidity. The 
modelling of plausible scenarios presented here, which have been informed by existing research 
on stigma, also suggests that the impact of stigma might be substantial. Indeed, where possible, 
in our modelling we sought to take a conservative approach. For example, the PMTCT model only 
considers those women who present at ANC services (versus the universe of pregnant women) and 
does not take into account how stigma might negatively a ect uptake or timing of presentation 
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at services. Furthermore, the model focuses on quantifying the impact of stigma on vertical HIV 
transmission and does not quantify the potential broader bene ts to women of  nding out their 
HIV status during the PMTCT care process.
Implications and conclusions
The model  ndings suggest that stigma has a large impact on mother-to-child transmission of HIV 
and that programmes that can e ectively reduce levels of stigma might reap many bene ts. To 
date, an appropriately large focus in PMTCT has been on strengthening the delivery of the medical 
components of PMTCT programming. This modelling highlights the additional importance of also 
investing in addressing stigma and other gender and social barriers to PMTCT.
This working paper has focused on the impact of stigma on the vertical transmission of HIV. 
However, it is important to recognise that the bene ts of reducing stigma at a community level 
will spread across most aspects of HIV programming. Investment in stigma reduction interventions 
alongside more “traditional” medical services programs will have a multiplying e ect within 
communities, which will impact not only PMTCT programmes but also ART programmes and 
other forms of HIV prevention and care. These bene ts might be far reaching, as stigma is such an 
important structural driver of the HIV epidemic and its consequences.
With potentially as many as half of vertical transmissions attributable to stigma, more investment 
in responding to stigma is an urgent need. Research is needed to increase understanding of 
women’s perspectives on PMTCT and how stigma and other gender-related factors impact 
participation in each step of the PMTCT process and to support evidence-based programming to 
respond e ectively to these factors.
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Appendix: PMTCT stigma model technical 
description
The spreadsheet model estimates the number of vertical HIV infections that would occur for 
di erent assumptions about the levels of stigma and their impact on PMTCT service delivery.
The model has the following inputs related to the ANC population being considered:
Number of women accessing ANC services – N ●
HIV prevalence among women accessing ANC services – p ●
Percentage of women who lose child during pregnancy or in  rst year of life – d ●
The model also has inputs describing the probability of vertical transmission in the  rst year of life:
Probability of mother-to-child HIV transmission in absence of PMTCT – p ● 0
Probability of MTCT when mother receives nevirapine but child does not, and not able to adhere  ●
to feeding guidelines – p1
Probability of MTCT when mother receives nevirapine but child does not, and able to adhere to  ●
feeding guidelines – p2
Probability of MTCT when mother and child receive nevirapine, and not able to adhere to  ●
feeding guidelines – p3
Probability of MTCT when mother and child receive nevirapine, and able to adhere to feeding  ●
guidelines – p4
The four sets of stigma inputs are as follows:
Proportion of women attending ANC who are o ered and accept HIV test – a ● i
Proportion of women who  nd out status, test HIV positive and take nevirapine – b ● i
Proportion of women testing HIV positive and receiving nevirapine whose baby receives infant  ●
dose – ci
Proportion of women testing HIV positive and receiving ART who are able to adhere to feeding  ●
guidelines – di
Where i ranges from 0 to 3, it denotes the associated level of stigma (i = 0, no stigma; 1, low stigma; 
2, medium stigma; and 3, high stigma).
For a speci ed level of stigma, i, the number of mother-to-child HIV infections (Ci) is given by the 
sum of infections from the following numbers of HIV-infected women whose babies do not die in 
the  rst year of life:
May or may not test, do not receive any PMTCT intervention, and do not follow the  ●
recommended feeding guidelines:
Np(1 – d)[ai (1 – bi) + (1 – ai)]p0
Test and receive nevirapine, child does not receive the infant dosage, and do not follow  ●
recommended feeding guidelines:
Np(1 – d) aibi(1 – ci)(1 – di)p1
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Test and receive nevirapine, child does not receive the infant dosage, and follow recommended  ●
feeding guidelines:
Np(1 – d)aibi(1 – ci)dip2
Test and receive nevirapine, child receives the infant dosage, and do not follow recommended  ●
feeding guidelines:
Np(1 – d)aibici(1 – di)p3
Test and receive nevirapine, child receives the infant dosage, and follow recommended feeding  ●
guidelines:
Np(1 – d)aibicidip4
That is, for i = 0 to 3,
Ci = Np(1 – d){[ai (1 – bi) + (1 – ai)]p0 + aibi(1 – ci)(1 – di)p1 + aibi(1 – ci)dip2 + aibici(1 – di)p3 + aibicidip4 }
The percentage of vertical HIV infections due to stigma is then calculated as follows:
High stigma = 100(C ● 3 – C0)/ C3
Medium stigma = 100(C ● 2 – C0)/ C3
Low stigma = 100(C ● 1 – C0)/ C3
Similarly, the percentage reduction in vertical HIV infections that would occur following reductions 
in stigma are calculated as follows:
High to medium stigma = 100(C ● 3 – C2)/ C3
High to low stigma = 100(C ● 3 – C1)/ C3
Medium to low stigma = 100(C ● 2 – C1)/ C3.
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